Miramont Wellness Centers has launched EXOMIND, a novel, FDA-cleared brain stimulation device for treating depression and related mental health disorders. The clinics—based in Fort Collins and Parker, Colorado—are currently the only providers in the state offering this innovative therapy with coverage under medical insurance plans.
EXOMIND leverages transcranial magnetic stimulation (TMS) to restore healthy neural activity in the brain’s frontal cortex, which governs mood and cognitive regulation. The rollout places Miramont Wellness Centers at the forefront of non-pharmacological mental health innovation, addressing a rising demand for drug-free depression interventions as national rates of anxiety and depressive disorders remain elevated post-COVID.
What is EXOMIND and how does it work?
EXOMIND is a next-generation TMS-based device developed to alleviate symptoms of depression, anxiety, obsessive behaviors, and related conditions. Unlike pharmaceutical antidepressants, which often take weeks to show efficacy and may cause side effects like fatigue or weight gain, EXOMIND delivers magnetic pulses directly to the frontal cortex. This stimulation aims to rebalance brain activity patterns associated with mood regulation, offering a safe and non-invasive alternative to medication.
The treatment protocol includes two pathways based on insurance eligibility. Covered patients typically undergo 18-minute sessions five times a week for six weeks, while uninsured or cash-pay individuals may opt for an accelerated protocol: six 30-minute sessions over three weeks.
Clinical studies and in-practice data suggest the treatment yields multiple benefits, including improved sleep, emotional resilience, reduced food cravings, and enhanced cognitive clarity. Many patients also report moderate weight loss—on average, four to five pounds—by the end of a treatment cycle.
Why Miramont Wellness Centers is betting on device-led mental health care
Dr. John Bender, M.D., M.B.A., CEO of Miramont Wellness Centers, emphasized that EXOMIND represents a paradigm shift in how mood disorders are addressed in the outpatient setting. “This technology is a fundamental shift in how we treat mood disorders,” said Dr. Bender. “It provides a medication-free path to recovery, using the brain’s own energy systems to restore balance.”
Miramont’s decision to pioneer EXOMIND deployment in Colorado reflects a broader healthcare trend: the rise of device-based neurotherapies as either alternatives or complements to pharmacological approaches. Over the past five years, market interest in TMS and related neurostimulation treatments has grown significantly, driven by efficacy in treatment-resistant depression and favorable safety profiles.
Insurance reimbursement has historically been a barrier to adoption, but Miramont’s integration of EXOMIND into its payer-covered services could accelerate mainstream accessibility. Analysts expect payer adoption to increase as evidence builds around the device’s clinical utility and long-term cost-effectiveness.
Expanded services underscore holistic health and wellness model
EXOMIND is part of a broader modernization effort across Miramont’s facilities. In addition to mental health support, the centers offer acute medical care, diagnostic imaging including X-ray and mammography, laboratory testing, and physical and mental therapy.
Miramont has also incorporated robotic medical assistants into its daily operations to streamline documentation and improve patient throughput. These autonomous systems help clinicians take notes during appointments, reducing administrative burden and allowing for more personalized care delivery.
In the aesthetic domain, Miramont MedSpa provides a comprehensive suite of services including dermaplaning, Botox, fillers, and laser treatments. Patients can also access minimally invasive cosmetic procedures such as face lifts and mommy makeovers.
In Fort Collins, the center additionally offers EMSELLA, a high-frequency muscle stimulation device for treating urinary incontinence. The procedure, which activates pelvic floor muscles while patients remain fully clothed, boasts a greater than 90% satisfaction rate and typically requires only 28 minutes per session.
Market reaction and early interest in EXOMIND rollout
While Miramont Wellness Centers is not a publicly traded company, early feedback from patients and medical professionals signals strong demand for EXOMIND. Mental health treatment devices are gaining traction as a credible investment thesis, with several early-stage medtech firms reporting double-digit growth rates in the neurostimulation segment.
Medical device analysts note that wider insurance coverage for outpatient TMS technologies, including EXOMIND, could open up a multi-billion-dollar market in the U.S. outpatient mental health space. Institutional healthcare investors are increasingly watching for clinics that pair cutting-edge treatments with cost-effective delivery models and high patient adherence.
EXOMIND’s inclusion in covered benefits may also influence competing clinics to follow suit, driving market-wide adoption of non-invasive mental health therapies.
Upcoming EXOMIND showcase to build public awareness
To raise community awareness, Miramont Wellness Centers is hosting a launch event for EXOMIND on August 6, 2025, at its Fort Collins location (4674 Snow Mesa Dr., STE 140). From 12–4 p.m., attendees can access a discounted private EXOMIND session, followed by a complimentary party from 4–7 p.m. The open house will feature refreshments, raffle prizes, and event-only promotional pricing.
Patients who pre-register for the event will receive added perks, including consultation opportunities with providers and early access to bundled wellness packages.
Miramont aims to use the event as a springboard to attract new patients while educating the public on the science and safety of magnetic brain stimulation. In parallel, the clinic plans to expand EXOMIND availability to its Parker location in Q4 2025, contingent on patient volume and clinical staffing.
Why EXOMIND and brain stimulation therapies are drawing attention in 2025
The EXOMIND debut at Miramont coincides with a broader surge in non-drug interventions for depression and anxiety. With mental health disorders now affecting over 20% of U.S. adults annually, according to the CDC, demand is rising for alternatives to long-term SSRI and SNRI prescriptions.
In the past decade, FDA-cleared neuromodulation devices like Deep TMS (BrainsWay), NeuroStar, and now EXOMIND have expanded access to outpatient treatment options that deliver meaningful results without medication-induced side effects.
Moreover, insurers are beginning to see TMS not just as a mental health service, but as a potential savings generator—cutting long-term costs by reducing hospitalization, emergency visits, and prescription loads.
By becoming the first Colorado-based clinic to offer EXOMIND under insurance coverage, Miramont is signaling its intent to be a statewide and potentially national leader in progressive, integrative wellness care.
What comes next for Miramont and brain stimulation care?
Following the EXOMIND rollout, Miramont Wellness Centers is expected to deepen its investment in neuromodulation and integrative therapies. Market watchers anticipate the clinic could explore additional device partnerships or clinical research collaborations to solidify its position as a regional innovation hub.
If initial results with EXOMIND lead to strong patient outcomes and payer satisfaction, analysts believe Miramont may emerge as a replicable model for mental health modernization in suburban and semi-urban U.S. markets.
For now, the clinic’s success will be measured by patient adoption, insurance continuity, and long-term health outcomes. But industry sentiment is optimistic: the convergence of FDA-approved neurotechnologies and accessible reimbursement could be the inflection point the outpatient mental health sector has long awaited.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
